This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strong Segmental Performance to Drive Stryker's Q3 Earnings
by Zacks Equity Research
SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Ecolab's Set to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
ECL third-quarter results are likely to reflect continued segmental strength.
Cardinal Health to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Despite recent supply chain challenges, new facilities and the acquisition of Specialty Networks are likely to have driven CAH's growth
Will Non-COVID-19 Diagnostics Sales Drive Hologic's Q4 Earnings?
by Zacks Equity Research
HOLX's fiscal 2024 fourth-quarter results are expected to reflect a solid performance of the Diagnostics business, led by the base Molecular franchise.
BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls
by Zacks Equity Research
Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.
Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
by Zacks Equity Research
Expanding transplant logistic service business is likely to have driven TransMedics' third-quarter 2024 performance.
Will CGM Sensor Demand Continue to Drive DexCom Q3 Earnings?
by Zacks Equity Research
DXCM's third-quarter 2024 results are likely to reflect rising volumes across all channels.
AVTR Stock Flat Following the Close of Divestiture Deal With Audax
by Zacks Equity Research
Avantor closes its deal with Audax to divest its clinical services business.
Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for West Pharmaceutical in Q3 Earnings?
by Zacks Equity Research
WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.
Henry Schein Stock Gains From Dental Business Expansion Amid Macro Woe
by Zacks Equity Research
Henry Schein strategically sets up distribution centers worldwide to better serve customers and increase its operating efficiency.
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
by Zacks Equity Research
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
BRKR Stock to Gain From Newly Formed Bruker Spatial Biology Division
by Zacks Equity Research
Bruker announces the formation of the new Bruker Spatial Biology division.
Why Masimo (MASI) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IDXX Gears Up for Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
IDEXX Laboratories' third-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
Will FARAPULSE Line Aid Boston Scientific's Q3 Earnings?
by Zacks Equity Research
BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.
Edwards Lifesciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third quarter.
Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus
by Zacks Equity Research
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.
DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.
Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock
by Zacks Equity Research
LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.
Here's Why You Should Add Masimo Stock to Your Portfolio Now
by Zacks Equity Research
MASI's R&D activities raise optimism about the stock.
Reasons to Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors, owing to its strong product portfolio.
Best Momentum Stocks to Buy for October 1st
by Zacks Equity Research
AU, MASI, and SKM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 1, 2024.